COMMUNIQUÉS West-GlobeNewswire

Immuron Reports Continued Sales Growth
19/01/2026
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative [...]
CUKTECH Launches 30 Ultra Charging Station in Malaysia, Redefining the Desktop Charging Experience
19/01/2026
KUALA LUMPUR, Malaysia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- CUKTECH has officially announced the launch of its flagship product, the CUKTECH 30 Ultra Charging Station , arriving in Malaysia at 8:00 PM on January 16, 2026 [...]
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
19/01/2026
TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
19/01/2026
COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]
Concept Life Sciences Appoints Dr Adam Davenport as CSO to Strengthen Leadership in Integrated Drug Discovery
19/01/2026
CHAPEL-EN-LE-FRITH, United Kingdom, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Concept Life Sciences, a leading global contract research organization (CRO) specialising in integrated drug discovery, development, and analytical [...]
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
19/01/2026
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant in South Korea [...]
IBA choisie par le MD Anderson Cancer Center pour fournir trois systèmes Proteus®ONE
19/01/2026
Louvain-la-Neuve, Belgique, le 19 janvier 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
IBA selected by MD Anderson Cancer Center to supply three Proteus®ONE systems
19/01/2026
Louvain-La-Neuve, Belgium, January 19, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer [...]
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
19/01/2026
Approval Label May Include Opioid Reduction NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided [...]
Phentermine Over the Counter Alternative 2026 - OTC Appetite Suppressant Search Trend Analysis Positions PhenQ as a Market Leader According to 1200 Doctors
17/01/2026
Consumer report about over-the-counter “phentermine alternative” search behavior, the OTC appetite suppressant market, and how PhenQ is positioned within the market. New York City, NY, Jan. 17, 2026 (GLOBE NEWSWIRE) -- [...]
4DMT Announces New Employment Inducement Grants
17/01/2026
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025
17/01/2026
Châtillon, France, 16 janvier 2026 DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW [...]
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
17/01/2026
Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is [...]
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
16/01/2026
MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ ( Bi [...]
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
16/01/2026
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
16/01/2026
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical- [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, [...]
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]

Pages